Limits...
Association of adiponectin with peripheral arterial disease and mortality in nondiabetic hemodialysis patients: Long-term follow-up data of 7 years

View Article: PubMed Central - PubMed

ABSTRACT

Background:: The relationships between adiponectin and clinical outcomes in hemodialysis (HD) patients remain highly controversial. Meanwhile, the association between adiponectin and the peripheral artery disease (PAD) has not been well studied in HD patients without diabetic mellitus.

Materials and methods:: The ankle-brachial index was measured in HD patients. Adiponectin levels in 105 HD patients were measured by Enzyme-Linked Immunosorbant Assay.

Results:: 105 HD patients were enrolled; 14 (13%) patients had PAD. Using receiver-operating-characteristic (ROC) curve analysis for PAD, adiponectin (area under the curve [AUC] 0.935, 95% confidence interval [CI]: 0.848–0.981, P < 0.001) showed significantly positive predictive value. During follow-up (mean 63 ± 30 months), 34 deaths (32%) occurred. Kaplan–Meier analysis found those patients lower median adiponectin had a significantly poor outcome (P < 0.05), and Cox analysis further confirmed that adiponectin was an independent predictor of overall mortality (hazard ratio [HR], 0.832, 95% CI: 0.696–0.995, P < 0.05). The ROC curve of overall mortality showed that the AUC of adiponectin was 0.719 (95% CI: 0.586–0.813, P < 0.05). In HD patients with PAD, the univariate analysis showed that adiponectin (HR, 0.649, 95% CI: 0.527–0.800, P < 0.001) was also associated with overall mortality.

Conclusion:: Decreasing levels of adiponectin were associated with a significant increase in the risk of PAD in HD patients without diabetic mellitus. Furthermore, as the results of our observation period (maximum of 7 years) showed, adiponectin was a predictor of all-cause mortality in HD patients.

No MeSH data available.


Kaplan–Meier plot of ankle-brachial index for cardiovascular mortality
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC5121992&req=5

Figure 3: Kaplan–Meier plot of ankle-brachial index for cardiovascular mortality

Mentions: About 16 CV deaths were documented during the follow-up period. We also analyzed the ABI values in predicting CV mortality and found that an ABI of less than 0.9 (HR, 3.283, 95% CI: 2.027–7.582; P < 0.001) was a strong predictor for CV mortality. Figure 3 showed the Kaplan–Meier analysis for CV mortality. Patients with an ABI of less than 0.9 had a worse CV survival compared with those with a normal ABI (P < 0.001).


Association of adiponectin with peripheral arterial disease and mortality in nondiabetic hemodialysis patients: Long-term follow-up data of 7 years
Kaplan–Meier plot of ankle-brachial index for cardiovascular mortality
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC5121992&req=5

Figure 3: Kaplan–Meier plot of ankle-brachial index for cardiovascular mortality
Mentions: About 16 CV deaths were documented during the follow-up period. We also analyzed the ABI values in predicting CV mortality and found that an ABI of less than 0.9 (HR, 3.283, 95% CI: 2.027–7.582; P < 0.001) was a strong predictor for CV mortality. Figure 3 showed the Kaplan–Meier analysis for CV mortality. Patients with an ABI of less than 0.9 had a worse CV survival compared with those with a normal ABI (P < 0.001).

View Article: PubMed Central - PubMed

ABSTRACT

Background:: The relationships between adiponectin and clinical outcomes in hemodialysis (HD) patients remain highly controversial. Meanwhile, the association between adiponectin and the peripheral artery disease (PAD) has not been well studied in HD patients without diabetic mellitus.

Materials and methods:: The ankle-brachial index was measured in HD patients. Adiponectin levels in 105 HD patients were measured by Enzyme-Linked Immunosorbant Assay.

Results:: 105 HD patients were enrolled; 14 (13%) patients had PAD. Using receiver-operating-characteristic (ROC) curve analysis for PAD, adiponectin (area under the curve [AUC] 0.935, 95% confidence interval [CI]: 0.848&ndash;0.981, P &lt; 0.001) showed significantly positive predictive value. During follow-up (mean 63 &plusmn; 30 months), 34 deaths (32%) occurred. Kaplan&ndash;Meier analysis found those patients lower median adiponectin had a significantly poor outcome (P &lt; 0.05), and Cox analysis further confirmed that adiponectin was an independent predictor of overall mortality (hazard ratio [HR], 0.832, 95% CI: 0.696&ndash;0.995, P &lt; 0.05). The ROC curve of overall mortality showed that the AUC of adiponectin was 0.719 (95% CI: 0.586&ndash;0.813, P &lt; 0.05). In HD patients with PAD, the univariate analysis showed that adiponectin (HR, 0.649, 95% CI: 0.527&ndash;0.800, P &lt; 0.001) was also associated with overall mortality.

Conclusion:: Decreasing levels of adiponectin were associated with a significant increase in the risk of PAD in HD patients without diabetic mellitus. Furthermore, as the results of our observation period (maximum of 7 years) showed, adiponectin was a predictor of all-cause mortality in HD patients.

No MeSH data available.